NASDAQ:ERNA Eterna Therapeutics (ERNA) Stock Price, News & Analysis → Invest in the 'Trojan Horse' of Alzheimer's Treatment (From Behind the Markets) (Ad) Free ERNA Stock Alerts $2.03 -0.09 (-4.25%) (As of 05/16/2024 ET) Add Compare Share Share Today's Range$2.03▼$2.2550-Day Range$1.74▼$2.4452-Week Range$0.84▼$2.99Volume13,022 shsAverage Volume10,049 shsMarket Capitalization$10.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Eterna Therapeutics alerts: Email Address Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Eterna Therapeutics Stock (NASDAQ:ERNA)Eterna Therapeutics Inc. operates as a preclinical-stage, biopharmaceutical company. The company offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. The company was formerly known as Brooklyn ImmunoTherapeutics, Inc. and changed its name to Eterna Therapeutics Inc. in October 2022. Eterna Therapeutics Inc. is based in Cambridge, Massachusetts.Read More ERNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ERNA Stock News HeadlinesMay 10, 2024 | globenewswire.comEterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory DiseasesMay 8, 2024 | globenewswire.comEterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory BoardMay 7, 2024 | finance.yahoo.comEterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory DiseasesMay 7, 2024 | finance.yahoo.comEterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M LocusMarch 27, 2024 | finance.yahoo.comQ4 2023 Cognition Therapeutics Inc Earnings CallMarch 26, 2024 | msn.comViking Therapeutics' experimental tablet helps reduce weight in small studyMarch 15, 2024 | investorplace.comERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023February 23, 2024 | benzinga.comEterna Therapeutics Stock (NASDAQ:ERNA) Dividends: History, Yield and DatesFebruary 20, 2024 | finance.yahoo.comEterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of DirectorsFebruary 20, 2024 | globenewswire.comEterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of DirectorsJanuary 12, 2024 | msn.comEterna Therapeutics files to sell 18.2M shares for holdersJanuary 3, 2024 | finance.yahoo.comEterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)December 21, 2023 | finance.yahoo.comEterna Therapeutics Appoints Sanjeev Luther as President and CEODecember 20, 2023 | msn.comEterna Therapeutics names Sanjeev Luther as CEODecember 20, 2023 | finance.yahoo.comEterna Therapeutics Names Sanjeev Luther as President and Chief Executive OfficerDecember 15, 2023 | msn.comEterna Therapeutics launches convertible debt and warrant financing of up to $9.2MDecember 14, 2023 | finance.yahoo.comEterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant FinancingDecember 6, 2023 | markets.businessinsider.comTreadwell Announces Strategic Pipeline Prioritization and Leadership TransitionsNovember 1, 2023 | finance.yahoo.comEterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of DirectorsOctober 30, 2023 | markets.businessinsider.comCalidi Biotherapeutics Names Andrew Jackson CFOOctober 30, 2023 | marketwatch.comCalidi Biotherapeutics Names Andrew Jackson Chief Financial OfficerOctober 5, 2023 | markets.businessinsider.comPositive Clinical Outcomes and Continued Genentech Support Bolster Buy Rating for Lineage Cell Therapeutics: An Analysis of OpRegen’s PotentialSeptember 13, 2023 | uk.finance.yahoo.comStem Cell Therapy Contract Manufacturing market is projected to grow at a CAGR of 12.4% by 2033: VisiongainSeptember 8, 2023 | finance.yahoo.comInsider Stock Buying Reaches US$2.7m On Eterna TherapeuticsSeptember 6, 2023 | finance.yahoo.comEterna Therapeutics Teams with Lineage Cell on Transplant TherapiesSee More Headlines Receive ERNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eterna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today5/16/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ERNA CUSIPN/A CIK748592 Webwww.brooklynitx.com Phone(212) 582-1199Fax760-438-3505Employees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,670,000.00 Net MarginsN/A Pretax Margin-31,869.12% Return on Equity-508.73% Return on Assets-53.03% Debt Debt-to-Equity Ratio3.03 Current Ratio1.46 Quick Ratio1.46 Sales & Book Value Annual Sales$70,000.00 Price / Sales156.89 Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / Book4.95Miscellaneous Outstanding Shares5,410,000Free Float3,493,000Market Cap$10.98 million OptionableNo Data Beta4.31 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMs. Sandra M. Gurrola (Age 57)Principal Financial & Accounting Officer and Senior VP of Finance Comp: $305.88kMr. Sanjeev Luther (Age 62)CEO, President & Director Ms. Dorothy J. Clarke (Age 58)General Counsel & Director Ms. Megan YungChief Strategy OfficerKey CompetitorsImunonNASDAQ:IMNNKiora PharmaceuticalsNASDAQ:KPRXPurple BiotechNASDAQ:PPBTRedHill BiopharmaNASDAQ:RDHLAkari TherapeuticsNASDAQ:AKTXView All CompetitorsInstitutional OwnershipAvidian Wealth Solutions LLCBought 14,798 shares on 5/3/2024Ownership: 0.274%Sippican Capital AdvisorsBought 18,750 shares on 5/2/2024Ownership: 1.346%View All Institutional Transactions ERNA Stock Analysis - Frequently Asked Questions How have ERNA shares performed in 2024? Eterna Therapeutics' stock was trading at $1.7950 on January 1st, 2024. Since then, ERNA stock has increased by 13.1% and is now trading at $2.03. View the best growth stocks for 2024 here. When is Eterna Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our ERNA earnings forecast. How were Eterna Therapeutics' earnings last quarter? Eterna Therapeutics Inc. (NASDAQ:ERNA) posted its quarterly earnings data on Thursday, March, 14th. The company reported ($1.14) EPS for the quarter. The business had revenue of $0.02 million for the quarter. Who are Eterna Therapeutics' major shareholders? Eterna Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Sippican Capital Advisors (1.35%) and Avidian Wealth Solutions LLC (0.27%). Insiders that own company stock include John D Halpern and Nicholas Jason Singer. View institutional ownership trends. How do I buy shares of Eterna Therapeutics? Shares of ERNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ERNA) was last updated on 5/17/2024 by MarketBeat.com Staff From Our Partners348 million Americans lives to END as we know it?The Oxford ClubCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceGold Set to EXPLODE!Gold Safe ExchangeInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the Markets[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsHow Biden has already won 2024Porter & CompanyA once-in-a-century investment opportunityStansberry ResearchCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eterna Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
